Pharma must show drug prices in ads—a transparency win for patients

What it does

This bill requires pharmaceutical manufacturers to disclose the wholesale acquisition cost (list price) of prescription drugs in direct-to-consumer advertisements, effective July 1, 2026, for drugs costing $35 or more per 30-day supply. Manufacturers who fail to comply face civil penalties up to $100,000 per violation. The bill aims to give consumers transparent pricing information so they can make informed decisions about whether they can afford medications before asking their doctor for them.

Why we flagged it

The bill's core mechanism is a disclosure requirement—manufacturers must reveal pricing information in advertisements. This is a transparency measure, not a price-control or subsidy mechanism. It operates by mandating information disclosure to consumers, not by restricting supply, capping prices, or redistributing funds.

What the text implies

• Manufacturers may respond by reducing DTC advertising volume for high-cost drugs, potentially reducing consumer awareness of treatment options (though the bill's findings suggest current advertising inflates demand for inappropriate or expensive alternatives).
• The $35 threshold exemption means lower-cost drugs remain exempt from disclosure, creating a two-tier advertising landscape where only expensive drugs require price transparency.
• Manufacturers may challenge the regulation as compelled commercial speech under the First Amendment; litigation risk is material but not addressed in the bill.
• Real-time pricing updates required by regulation may impose compliance costs on manufacturers, potentially passed to consumers through higher list prices or reduced advertising budgets.
• The bill relies on HHS rulemaking (due within 1 year) to define visual/audio standards and update timelines; final implementation details remain uncertain and subject to agency discretion.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain access to objective pricing information that was previously available only to industry insiders and expensive subscription services, enabling them to make informed decisions about medication affordability before committing to therapy. The requirement does not restrict access to medications, impose new costs on patients, or create barriers to treatment—it only mandates transparency in advertising that already occurs.

Named in the bill

Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Pharmaceutical manufacturers, Medicare, Medicaid

Where it stands

9 cosponsors: 4 Democrats, 4 Republicans, 1 Independents.

• Jan 23, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 23, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 8 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,945,904 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.

• American Academy of Family Physicians — $1,715,904 on 2 filings
• The Campaign for Sustainable Rx Pricing — $180,000 on 2 filings
• Campaign for Sustainable Drug Pricing (csrxp) — $50,000 on 1 filing
• Coalition for Healthcare Communications — $0 on 3 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.